Serological investigations of blood donors from the city and area around Magdeburg for antibodies against SARS-CoV-2 (COVID-19)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023263

Enrollment

4500

Registered

2020-12-04

Start date

2021-01-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Serological testing of antibodies against SARS-CoV-2 and an analysis of differences between symptomatic and asymptomatic COVID19 courses.

Interventions

Group 1: Collection and testing of blood samples from whole blood donations from up to four specific points in time (blood sample-1: approximately 2,000 blood samples from 2,000 whole blood donations,

blood sample-2: approximately 2,000 blood samples from 2. 000 whole blood donations, July/August 2021

blood sample-3: approximately 2,000 blood samples from 2,000 whole blood donations, Dec 2021 - Feb 2022

blood sample-4: approximately 2,000 blood samples from 2,000 whole blood donations, June/July 2022 (if possible, blood samples are obtained from the same donors). Group 2: Testing of approximately 2,

Eligibility

Sex/Gender

All

Age

18 Years to 72 Years

Inclusion criteria

Inclusion criteria: 18 years and interest in blood donation.

Exclusion criteria

Exclusion criteria: The exclusion criteria are based on the German Medical Association’s donor exclusion criteria

Design outcomes

Primary

Measure	Time frame
The frequency of IgG antibodies against SARS-CoV-2 in blood donors will be determined by serological analysis of blood samples over a period of approximately 18 - 21 months and the development over this period will be monitored. Measurement period: BP-0: approximately 2,000 available samples from 2019 period. BP-1: approx. 2,000 donors, period: January 21, 2021 to April 30, 2021 BP-2: approx. 2,000 donors, period: July 01 to October 31, 2021 BP-3: approx. 2,000 donors, period: January 24, 2022 to April 30, 2022 BP-4: approx. 2,000 donors, period: July 1, 2022 to October 31 2022 Measurement method: Serological examination by blood collection.	—

Measure

Time frame

The frequency of IgG antibodies against SARS-CoV-2 in blood donors will be determined by serological analysis of blood samples over a period of approximately 18 - 21 months and the development over this period will be monitored. Measurement period: BP-0: approximately 2,000 available samples from 2019 period. BP-1: approx. 2,000 donors, period: January 21, 2021 to April 30, 2021 BP-2: approx. 2,000 donors, period: July 01 to October 31, 2021 BP-3: approx. 2,000 donors, period: January 24, 2022 to April 30, 2022 BP-4: approx. 2,000 donors, period: July 1, 2022 to October 31 2022 Measurement method: Serological examination by blood collection.

—

Secondary

Measure	Time frame
To examine the influence of age, gender, occupational activities, home conditions, and frequency of family and other social contacts on the frequency of SARS-CoV2 antibodies. To analyze differences between participants* with symptomatic and asymptomatic COVID19 histories To survey vaccination readiness, vaccination attitudes, and the effect of a vaccination campaign on them, if applicable To analyze the impact of vaccines on antibody detection rates. The comparison of different antibody tests (test quality). Measurement methods: Questionnaires and blood samples.	—

Measure

Time frame

To examine the influence of age, gender, occupational activities, home conditions, and frequency of family and other social contacts on the frequency of SARS-CoV2 antibodies. To analyze differences between participants* with symptomatic and asymptomatic COVID19 histories To survey vaccination readiness, vaccination attitudes, and the effect of a vaccination campaign on them, if applicable To analyze the impact of vaccines on antibody detection rates. The comparison of different antibody tests (test quality). Measurement methods: Questionnaires and blood samples.

—

Countries

Germany

Contacts

Public ContactStephan Krämer

Institut für Transfusionsmedizin und Immunhämatologie mit Blutbank

stephan.kraemer@med.ovgu.de0391-67-13700

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 9, 2026